ChiCTR2000030800 版本V1.1 版本创建时间2020/03/15 09:23:57 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000030800 

最近更新日期:

Date of Last Refreshed on:

2020-03-15 09:21:53 

注册时间:

Date of Registration:

2020-03-15 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

新型冠状病毒肺炎(COVID-19)患者外周血炎症因子水平及其诊断预后价值的研究

Public title:

Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia (COVID-19) and their diagnostic and prognostic value

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新型冠状病毒肺炎患者外周血炎症因子水平及其诊断预后价值的研究

Scientific title:

Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia and their diagnostic and prognostic value

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴凯峰 

研究负责人:

吴凯峰 

Applicant:

Wu Kaifeng 

Study leader:

Wu Kaifeng 

申请注册联系人电话:

Applicant telephone:

+86 13788989286

研究负责人电话:

Study leader's telephone:

+86 13788989286

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

kiphoonwu@126.com

研究负责人电子邮件:

Study leader's E-mail:

kiphoonwu@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

贵州省遵义市汇川区凤凰路98号

研究负责人通讯地址:

贵州省遵义市汇川区凤凰路98号

Applicant address:

98 Fenghuang Road, Huichuan District, Zunyi, Guizhou, China

Study leader's address:

98 Fenghuang Road, Huichuan District, Zunyi, Guizhou, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

遵义医科大学第三附属医院(遵义市第一人民医院)

Applicant's institution:

The Third Affiliated Hospital of Zunyi Medical University

研究负责人所在单位:

遵义医科大学第三附属医院(遵义市第一人民医院)

Affiliation of the Leader:

The Third Affiliated Hospital of Zunyi Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审(2020)03号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

遵义市第一人民医院伦理委员会

Name of the ethic committee:

The ethic committee of the first people's hospital of Zunyi

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

屠琳

Contact Name of the ethic committee:

Tu Lin

伦理委员会联系地址:

贵州省遵义市汇川区凤凰路98号

Contact Address of the ethic committee:

98 Fenghuang Road, Huichuan District, Zunyi, Guizhou, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

遵义医科大学第三附属医院(遵义市第一人民医院)

Primary sponsor:

The Third Affiliated Hospital of Zunyi Medical University

研究实施负责(组长)单位地址:

贵州省遵义市汇川区凤凰路98号

Primary sponsor's address:

98 Fenghuang Road, Huichuan District, Zunyi, Guizhou, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

贵州

市(区县):

遵义

Country:

China

Province:

Guizhou

City:

Zunyi

单位(医院):

遵义医科大学第三附属医院(遵义市第一人民医院)

具体地址:

贵州省遵义市汇川区凤凰路98号

Institution
hospital:

The Third Affiliated Hospital of Zunyi Medical University

Address:

98 Fenghuang Road, Huichuan District

经费或物资来源:

遵义市联合科技项目

Source(s) of funding:

Scientific project jointly provided by Zunyi science and technology bureau and the first people's hospital of Zunyi

Target disease:

COVID-19

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

1. 分析新冠病毒感染肺炎患者体内炎症因子及可溶性粘附因子表达水平,并明确差异表达分子; 2. 明确差异表达炎症因子及可溶性粘附分子在疾病分级、治疗指导、预后判断中的临床应用价值。  

Objectives of Study:

1. To analyze the expression levels of inflammatory factors and soluble adhesion factors in patients with COVID-19, and identify differentially expressed molecules; 2. To calrify the clinical application value of differentially expressed inflammatory factors and soluble adhesion molecules in disease classification, treatment guidance and prognosis judgment for COVID-19.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

参考国家卫生健康委员会文件《新型冠状病毒肺炎诊疗方案(试行第六版)》.

Inclusion criteria

Refer to the national health commission document "diagnosis and treatment plan of new coronavirus pneumonia (trial sixth edition)".

排除标准:

Exclusion criteria:

none

研究实施时间:

Study execute time:

From 2020-02-01 00:00:00 To 2021-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-02-01 00:00:00 To 2020-03-06 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

流行病学史 + CT + 临床表现 + SARS-Cov-2核酸阳性

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Epidemiological history + CT + clinical manifestations + sars-cov-2 nucleic acid positive

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

炎症因子和粘附分子 ELISA检测

Index test:

Elisa analysis of validation factors, inflammatory factors, adhesion factors

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

新冠肺炎患者

例数:

Sample size:

22

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Convid-19 cases

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

新冠疑似病人和正常健康人

例数:

Sample size:

57

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

Covid-19 suspected patients

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

贵州 

市(区县):

遵义 

Country:

China 

Province:

Guizhou 

City:

Zunyi 

单位(医院):

遵义医科大学第三附属医院(遵义市第一人民医院) 

单位级别:

三甲医院 

Institution
hospital:

The Third Affiliated Hospital of Zunyi Medical University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

serum

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 86 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

向研究者索取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

E-mail to the researcher

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-03-15 08:06:54